Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

176
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
176

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Ecnoglutide: First Approvals.

Drugs·2026
Same author

Tividenofusp Alfa: First Approval.

Molecular diagnosis & therapy·2026
Same author

Milsaperidone: First Approval.

Clinical drug investigation·2026
Same author

Narsoplimab: First Approval.

Drugs·2026
Same author

Aficamten: First Approval.

Drugs·2026
Same author

Elamipretide: First Approval.

Drugs·2025

Related Experiment Video

Updated: Jul 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K

Zilucoplan: First Approval.

Matt Shirley1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. dru@adis.com.

Drugs
|December 13, 2023
PubMed
Summary
This summary is machine-generated.

Zilucoplan (Zilbrysq®) is a new C5 inhibitor for generalized myasthenia gravis (gMG). It has gained initial approvals in Japan, the USA, and the EU for specific adult gMG patient populations.

More Related Videos

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.0K
Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure
06:39

Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure

Published on: August 28, 2009

14.1K

Related Experiment Videos

Last Updated: Jul 8, 2025

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
06:14

Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients

Published on: October 15, 2017

8.3K
A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System
13:22

A Chemical Screening Procedure for Glucocorticoid Signaling with a Zebrafish Larva Luciferase Reporter System

Published on: September 10, 2013

12.0K
Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure
06:39

Bioluminescence Imaging of Heme Oxygenase-1 Upregulation in the Gua Sha Procedure

Published on: August 28, 2009

14.1K

Area of Science:

  • Pharmacology
  • Immunology
  • Neurology

Background:

  • Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting neuromuscular junctions.
  • Current treatments for gMG have limitations, necessitating novel therapeutic approaches.
  • Complement component 5 (C5) plays a crucial role in the pathophysiology of gMG.

Purpose of the Study:

  • To summarize the key development milestones of zilucoplan (Zilbrysq®).
  • To highlight the regulatory approvals of zilucoplan for generalized myasthenia gravis.

Main Methods:

  • Review of preclinical and clinical development data for zilucoplan.
  • Analysis of regulatory submission and approval timelines.
  • Summary of pivotal trial outcomes and patient population characteristics.

Main Results:

  • Zilucoplan, a subcutaneously administered C5 inhibitor, demonstrated efficacy in adult patients with gMG.
  • First approval granted in Japan (September 2023) for steroid-refractory or immunosuppressant-intolerant anti-acetylcholine receptor (AChR) antibody-positive gMG patients.
  • Subsequent approvals in the USA (October 2023) and EU (December 2023) for similar patient populations.

Conclusions:

  • Zilucoplan represents a significant advancement in the treatment of generalized myasthenia gravis.
  • The drug's development and approval milestones underscore its therapeutic potential.
  • Ongoing regulatory reviews in Australia and Canada may expand patient access to zilucoplan.